BR112015023542A8 - uso de uma quantidade terapeuticamente eficaz de uma composição compreendendo adamts13 isolado - Google Patents

uso de uma quantidade terapeuticamente eficaz de uma composição compreendendo adamts13 isolado Download PDF

Info

Publication number
BR112015023542A8
BR112015023542A8 BR112015023542A BR112015023542A BR112015023542A8 BR 112015023542 A8 BR112015023542 A8 BR 112015023542A8 BR 112015023542 A BR112015023542 A BR 112015023542A BR 112015023542 A BR112015023542 A BR 112015023542A BR 112015023542 A8 BR112015023542 A8 BR 112015023542A8
Authority
BR
Brazil
Prior art keywords
composition
effective amount
therapeutically effective
adamts13
isolated adamts13
Prior art date
Application number
BR112015023542A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015023542A2 (pt
Inventor
Nathalie Schiviz Alexandra
Plaimauer Barbara
Muchitsch Eva-Maria
Rottensteiner Hanspeter
Hoellriegl Werner
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Publication of BR112015023542A2 publication Critical patent/BR112015023542A2/pt
Publication of BR112015023542A8 publication Critical patent/BR112015023542A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
BR112015023542A 2013-03-15 2014-03-13 uso de uma quantidade terapeuticamente eficaz de uma composição compreendendo adamts13 isolado BR112015023542A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794659P 2013-03-15 2013-03-15
PCT/US2014/026747 WO2014151968A1 (en) 2013-03-15 2014-03-13 Subcutaneous administration of adamts13

Publications (2)

Publication Number Publication Date
BR112015023542A2 BR112015023542A2 (pt) 2017-07-18
BR112015023542A8 true BR112015023542A8 (pt) 2019-12-03

Family

ID=50549463

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023542A BR112015023542A8 (pt) 2013-03-15 2014-03-13 uso de uma quantidade terapeuticamente eficaz de uma composição compreendendo adamts13 isolado

Country Status (18)

Country Link
US (4) US9611467B2 (https=)
EP (2) EP2968483B1 (https=)
JP (4) JP6484216B2 (https=)
KR (5) KR102513872B1 (https=)
CN (2) CN105407912A (https=)
AU (5) AU2013203062C1 (https=)
BR (1) BR112015023542A8 (https=)
CA (1) CA2905058A1 (https=)
DK (1) DK2968483T3 (https=)
EA (2) EA034546B1 (https=)
ES (1) ES2906550T3 (https=)
IL (3) IL241305B (https=)
MX (2) MX380485B (https=)
PL (1) PL2968483T3 (https=)
PT (1) PT2968483T (https=)
SG (3) SG11201507271QA (https=)
TW (4) TW202313664A (https=)
WO (1) WO2014151968A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
GB201510870D0 (en) * 2015-05-26 2015-08-05 Baxalta Inc And Katholieke Universiteit Leuven And Baxalta Gmbh Treatment of infarction
IL264372B2 (en) 2016-08-04 2024-05-01 Baxalta Inc Adamts13 for use in treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease
WO2020214033A1 (en) * 2019-04-17 2020-10-22 Erasmus University Medical Center Rotterdam Papain-like cysteine peptidase medicaments and uses thereof
WO2021067668A1 (en) 2019-10-04 2021-04-08 The Children's Medical Center Corporation Adamts13 treatment to enhance graft survival
US20230203469A1 (en) * 2020-04-02 2023-06-29 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof
CN115835904A (zh) * 2020-05-22 2023-03-21 武田药品工业有限公司 用于治疗和诊断冠状病毒疾病并发症的adamts13组合物和方法
WO2021242092A1 (en) * 2020-05-25 2021-12-02 Sanquin Innovatie B.V. Adamts13 protein variants and uses thereof
US20230405096A1 (en) * 2020-11-18 2023-12-21 Green Cross Corporation Adamts13 variant having increased escaping rate or activity against autoantibody
GB202102208D0 (en) * 2021-02-17 2021-03-31 Univ Manchester Adamts13 variant
WO2024151093A1 (ko) * 2023-01-11 2024-07-18 주식회사 녹십자 혈전성 질환의 예방 또는 치료를 위한 신규한 액상 제형물
JPWO2024224687A1 (https=) 2023-04-25 2024-10-31

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A (en) 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
AU2002336367A1 (en) 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
ATE544866T1 (de) * 2005-06-17 2012-02-15 Baxter Int Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
JP2009539757A (ja) * 2006-06-16 2009-11-19 バクスター・インターナショナル・インコーポレイテッド 血栓溶解活性を有するａｄａｍｔｓ１３含有組成物
AU2009246603B8 (en) * 2008-05-12 2015-08-13 Children's Medical Center Corporation von Willebrand Factor (VWF) inhibitors for treatment or prevention of infarction
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
PL4218797T3 (pl) * 2009-09-21 2025-02-10 Takeda Pharmaceutical Company Limited Stabilizowane płynne i liofilizowane preparaty adamts13
WO2012006594A1 (en) * 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
AU2013203062C1 (en) * 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13

Also Published As

Publication number Publication date
US20140271611A1 (en) 2014-09-18
US9611467B2 (en) 2017-04-04
MX2015012783A (es) 2016-04-28
EA034546B1 (ru) 2020-02-19
AU2020202738A1 (en) 2020-05-14
AU2022211908A1 (en) 2022-09-01
BR112015023542A2 (pt) 2017-07-18
US11779635B2 (en) 2023-10-10
JP2016517421A (ja) 2016-06-16
WO2014151968A8 (en) 2015-10-15
KR102218489B1 (ko) 2021-02-22
KR102102087B1 (ko) 2020-04-20
JP6484216B2 (ja) 2019-03-13
IL273365B (en) 2022-05-01
CA2905058A1 (en) 2014-09-25
KR102513872B1 (ko) 2023-03-27
KR20220027266A (ko) 2022-03-07
ES2906550T3 (es) 2022-04-19
MX380485B (es) 2025-03-12
KR20210021107A (ko) 2021-02-24
TWI740207B (zh) 2021-09-21
KR20160016756A (ko) 2016-02-15
EP2968483B1 (en) 2021-12-01
TW201513881A (zh) 2015-04-16
US10413600B2 (en) 2019-09-17
IL290486B2 (en) 2023-08-01
AU2013203062A1 (en) 2014-10-02
US20200101144A1 (en) 2020-04-02
JP6998333B2 (ja) 2022-02-10
US11185575B2 (en) 2021-11-30
AU2018203665A1 (en) 2018-06-14
SG11201507271QA (en) 2015-10-29
KR20190022926A (ko) 2019-03-06
AU2013203062C1 (en) 2018-06-28
EA201591758A1 (ru) 2016-03-31
AU2022211908B2 (en) 2023-11-30
CN105407912A (zh) 2016-03-16
EP2968483A1 (en) 2016-01-20
IL273365A (en) 2020-05-31
NZ749570A (en) 2020-11-27
AU2013203062B2 (en) 2016-06-23
KR102365936B1 (ko) 2022-02-23
US20220080032A1 (en) 2022-03-17
TWI690326B (zh) 2020-04-11
EP3960196A1 (en) 2022-03-02
AU2016231547A1 (en) 2016-10-06
KR20200041394A (ko) 2020-04-21
IL290486B1 (en) 2023-04-01
TWI786563B (zh) 2022-12-11
CN114259558A (zh) 2022-04-01
TW202138003A (zh) 2021-10-16
JP2022027991A (ja) 2022-02-14
IL290486A (en) 2022-04-01
JP7238088B2 (ja) 2023-03-13
IL241305A0 (en) 2015-11-30
HK1220131A1 (zh) 2017-04-28
NZ751610A (en) 2020-11-27
JP2023071821A (ja) 2023-05-23
MX2021002513A (es) 2021-04-28
PT2968483T (pt) 2022-02-23
DK2968483T3 (da) 2022-02-14
JP2019142850A (ja) 2019-08-29
US20170224785A1 (en) 2017-08-10
PL2968483T3 (pl) 2022-04-04
NZ712440A (en) 2020-11-27
TW202313664A (zh) 2023-04-01
TW202017591A (zh) 2020-05-16
EA201591758A8 (ru) 2017-03-31
AU2018203665B2 (en) 2020-01-30
IL241305B (en) 2020-04-30
AU2016231547B2 (en) 2018-03-15
EA201992832A1 (ru) 2020-05-31
SG10201707074TA (en) 2017-10-30
SG10202001227QA (en) 2020-03-30
AU2020202738B2 (en) 2022-06-09
WO2014151968A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
BR112015023542A8 (pt) uso de uma quantidade terapeuticamente eficaz de uma composição compreendendo adamts13 isolado
BR112015007985A8 (pt) uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
BR112015026095A2 (pt) métodos para controlar a dosagem de uma droga antitumoral administrada a um paciente com câncer, para administração de pelo menos uma droga antitumoral em duas doses separadas em um paciente com câncer e para seleção de pelo menos uma droga antitumoral
BR112015022181A8 (pt) proteínas da substância de inibição mulleriana (mis) e usos das mesmas para o tratamento de doenças
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MX381475B (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
BR112015021888A2 (pt) inibidores de dna-ik
MX390627B (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
NI201700032A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico
BR112016003229A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
MX391720B (es) Terapia combinada para tratar cáncer.
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX377089B (es) Uso de una proteína angiopoyetina modificada en la preparación de un medicamento para prevenir o tratar la malaria cerebral.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112015022825A2 (pt) métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]